[REF] UBP-T01012K
[Packing specification] 12Tests/Kit
[Intended use]
UltraDx NRAS Mutation Detection Kit can be used to qualitatively detect mutations of codon 12, 13 and 61 of NRAS gene in tissue samples of patients with malignant tumors (lung cancer, colorectal cancer, pancreatic cancer, nasopharyngeal carcinoma and other solid tumors), so as to provide the basis for individual drug therapy. NRAS gene mutation is associated with primary drug resistance of targeted drugs to EGFR signal transduction pathway in patients with malignant tumors. Patients with wild type of NRAS gene are likely to benefit from the treatment of Erbitux, (also known as Cetuximab) or Vectibix (also known as Panitumumab), Iressaor Tarceva, while malignant tumor patients with NRAS gene mutation do not significantly benefit from such targeted drug therapy.